Type 2 Diabetes Connect
  • Saved

4yr
Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population - PubMed

Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35414304/

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly prescribed medications for patients with type 2 diabetes mellitus (T2DM) based on cardiovascular benefits. Objective: This study aimed to evaluate efficacy...



Conclusion: The results of this study indicate no difference between liraglutide and semaglutide in terms of A1c-lowering potential, but it provides insights into key considerations for the Veteran population.

  • Saved

4yr
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Source : https://www.journal-of-hepatology.eu/article/S0168-8278(22)00235-5/fulltext

Non-alcoholic steatohepatitis (NASH) is associated with increased risk of liver-related and cardiovascular morbidity and mortality. Given the complex pathophysiology of NASH, combining therapies with complementary mechanisms may be beneficial. This...



Conclusions: In patients with mild-to-moderate fibrosis due to NASH, semaglutide with firsocostat and/or cilofexor was generally well tolerated. In exploratory efficacy analyses, treatment resulted in additional improvements in liver steatosis and biochemistry vs. semaglutide alone. Given this was a small-scale open-label trial, double-blind...

  • Saved

4yr
The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice - PubMed

The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35427802/

the mTOR pathway was attenuated, and the insulin signaling and the AMPK pathway were enhanced by semaglutide, ameliorating the liver gene expressions related to the metabolism of obese mice. These...



Conclusion: - the mTOR pathway was attenuated, and the insulin signaling and the AMPK pathway were enhanced by semaglutide, ameliorating the liver gene expressions related to the metabolism of obese mice. These findings are promising in delaying the progression of nonalcoholic fatty liver disease.


  • 4yr
    glucagon-like peptide type 1 receptor agonist (GLP-1) is indicated to treat obesity-related liver metabolic alterations.
  • Saved

4yr
Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients - Journal of Endocrinological Investigation

Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients - Journal of Endocrinological Investigation

Source : https://link.springer.com/article/10.1007/s40618-022-01799-2

Purpose Registered trials and real-world evidence (RWE) studies provided evidence on the efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk factors as add-on or de-novo treatment in type...



Conclusions: Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.

  • Saved

made a Post

4yr
Type 2 Diabetes

Over 34 million1 Americans have diabetes, and 90-95%2 of them have Type 2 Diabetes. When diet and lifestyle changes fail to improve glycemic control, metformin3 is typically the first treatment prescribed. Several novel drugs and classes have emerged to treat Type 2 Diabetes after or in addition to metformin. These include GLP-1 receptor agonists, DPP-4 and SGLT2 inhibitors.




  • What factors do you consider when adding to or switching from metformin?

  • What have been your experiences with some of the newer/novel Type 2 Diabetes drugs and classes?



 



References:




  1. National Diabetes Statistics Report, 2020

  2. CDC Diabetes Basics, accessed 11 Jan 2022

  3. Mayo Clinic Type 2 Diabetes Diagnosis and Treatment, accessed 11 Jan 2022


  • 4yr
    Incretin therapy is key as there is a relative deficiency or decreased responsiveness in metabolic syndrome and type 2 DM. With the GIP moiety being added to the GLP-1 Show More
  • 4yr
    Rybelsus ( it is oral Ozempic Semaglutide ) has come up as a block buster diabetic medicine in both managing diabetes and Obeisty , having phenomenal results that Show More

Show More Comments